Skip to main content

Table 2 Summary of methodological approaches used in the community-based neuropathological studies summarized in this review

From: Prevalence of mixed pathologies in the aging brain

Study

n

Neuropathological criteria

Aβ

Tau

α-Syn

Ubi/p62

TDP-43

Vascular pathologies

HS

  

BB

C

NR

NA

DLB/Br

       

MAP [27],[30]-[33]

425

+

+

+

 

+a

+

+

+

  

+

+

ROS [27],[30],[32]-[35]

539

+

+

+

 

+a

+

+

+

 

+b

+

+

MRC CFAS [21],[36]-[39]

525

+

+

  

+a,c

+

+

+

+

 

+

+

CC75C + [40]

224

+

+

  

+a

+

+

+

+

 

+

+

Vantaa 85 + d[41]-[43]

304

+

+

  

+a

+

+

+

+

 

+

+

Hisayama [44],[45]

205

+

 

+

 

+e

 

+

+

+

 

+

 

HAAS [46]-[48]

439

+

+

  

+e

  

+

+

 

+

+

ACT [49],[50]

438

+

+

+

 

+e

  

+

  

+

+

BALS [51],[52]

209

+

+

  

+e

  

+

  

+

 

OBASd[53],[54]

125

+

+

+

 

+e

 

+

+

  

+

+

90+ Studyd[55]

108

+

+

  

+e

+

+

+

 

+

+

+

VITA [5]

233

+

+

+

+

+c

+

+

+

+

+

+

+

  1. Aα, amyloid beta; ACT, Adult Changes in Thought; α-Syn, α-synuclein; BALS, Baltimore Longitudinal Study of Ageing; BB, Braak and Braak staging for Alzheimer’s disease; Br, Braak; C, Consortium to Establish a Registry for AD criteria; CC75C, Cambridge City Over-75’s Cohort; DLB, McKeith criteria for dementia with Lewy bodies; HAAS, Honolulu–Asia Aging Study; HS, hippocampal sclerosis; MAP, Rush Memory and Aging Project; MRC CFAS, Medical Research Council Cognitive Function and Ageing Study; n, number of individuals included in the studies; NA, National Institute on Aging–Alzheimer’s Association criteria; NR, National Institute on Aging–Reagan criteria; OBAS, Oregon Brain Aging Study; ROS, Religious Orders Study; TDP-43,Tar-DNA binding protein 43; Ubi, ubiquitin; VITA, Vienna Trans-Danube Aging study. aDLB criteria 1996. bNot assessed in all participants. cBraak staging for Parkinson’s disease. dAge of autopsied cohort >90 years. eDLB criteria 2005.